Thelansis

Microvillus Inclusion Disease (MVID) Market Outlook Thelansis’s “Microvillus Inclusion Disease (MVID) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Microvillus Inclusion Disease (MVID) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Microvillus Inclusion Disease (MVID) Overview Microvillus inclusion disease (MVID) is an ultra-rare, life-threatening congenital enteropathy caused by autosomal recessive loss-of-function mutations in MYO5B — encoding myosin Vb, critical for apical membrane trafficking and brush border formation — and less commonly STX3 and STXBP2, disrupting enterocyte polarity and microvillus assembly. The ...

Microvillus Inclusion Disease (MVID) Market Outlook Thelansis’s “ ⁠ Microvillus Inclusion Disease (MVID) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 ”  covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential ⁠ Microvillus Inclusion Disease (MVID) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China) . Key business questions answered: How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market...

Microvillus Inclusion Disease (MVID) Market Outlook Thelansis’s “Microvillus Inclusion Disease (MVID) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Microvillus Inclusion Disease (MVID) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the grea...

Microvillus Inclusion Disease (MVID) Market Outlook Thelansis’s “Microvillus Inclusion Disease (MVID) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Microvillus Inclusion Disease (MVID) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Microvillus Inclusion Disease (MVID) Overview Microvillus Inclusion Disease (MVID) is a rare, autosomal recessive congenital enteropathy characterized by severe, intractable secretory diarrhea and profound malabsorption, typically presenting within the first days of life. Affected infants may experience rapid fluid loss—sometimes up to 30% of body weight within 24 hours—leading to life-threatenin...

 Microvillus inclusion disease (MVID) is a rare inherited, and invariably deadly enteropathy, characterized by severe, intractable secretory diarrhea and nutrient malabsorption. This diarrhea becomes so abundant that within 24H, the children can lose up to 30% of their body weight, resulting in profound metabolic acidosis and severe dehydration. MVID is diagnosed by evaluating symptoms, excluding more common causes of diarrhea, and evaluating intestinal biopsies. Intestinal biopsies of patients with MVID show villus hypoplasia in the small intestine but no signs of infection or inflammation. MVID is caused by loss of function changes (mutations) in the myosin Vb (Myo5b) gene, a molecular motor gene responsible for the traffic of proteins into the brush border of epithelial cells. Mutations cause most cases of MVID in Myo5b. However, mutations in syntaxin 3, a gene for a SNARE protein responsible for vesicle fusion with the membrane, have been reported in some patients with MVID wit...